IL152590A0 - Treatment of congestive heart failure - Google Patents

Treatment of congestive heart failure

Info

Publication number
IL152590A0
IL152590A0 IL15259001A IL15259001A IL152590A0 IL 152590 A0 IL152590 A0 IL 152590A0 IL 15259001 A IL15259001 A IL 15259001A IL 15259001 A IL15259001 A IL 15259001A IL 152590 A0 IL152590 A0 IL 152590A0
Authority
IL
Israel
Prior art keywords
heart failure
congestive heart
hydrogen
treatment
excretion
Prior art date
Application number
IL15259001A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of IL152590A0 publication Critical patent/IL152590A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL15259001A 2000-05-03 2001-03-22 Treatment of congestive heart failure IL152590A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20143100P 2000-05-03 2000-05-03
PCT/US2001/009265 WO2001082920A2 (fr) 2000-05-03 2001-03-22 Traitement de l'insuffisance cardiaque congestive

Publications (1)

Publication Number Publication Date
IL152590A0 true IL152590A0 (en) 2003-05-29

Family

ID=22745788

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15259001A IL152590A0 (en) 2000-05-03 2001-03-22 Treatment of congestive heart failure

Country Status (19)

Country Link
EP (1) EP1280555B8 (fr)
JP (1) JP2003535823A (fr)
KR (1) KR20020093971A (fr)
CN (1) CN1431915A (fr)
AT (1) ATE326241T1 (fr)
AU (1) AU2001249364A1 (fr)
BR (1) BR0110566A (fr)
CA (1) CA2407929C (fr)
CZ (1) CZ20023587A3 (fr)
DE (1) DE60119723T2 (fr)
ES (1) ES2264444T3 (fr)
HU (1) HUP0300632A3 (fr)
IL (1) IL152590A0 (fr)
MX (1) MXPA02010865A (fr)
NZ (1) NZ522641A (fr)
PL (1) PL358544A1 (fr)
SK (1) SK15532002A3 (fr)
WO (1) WO2001082920A2 (fr)
ZA (1) ZA200209367B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
WO2019141575A1 (fr) * 2018-01-16 2019-07-25 Bayer Aktiengesellschaft Assistance dans le cadre du traitement de l'insuffisance cardiaque
KR20220052561A (ko) 2020-10-21 2022-04-28 장영진 어류 가공물 및/또는 콩 가공물을 유효성분으로 포함하는 심부전의 예방 또는 치료용 약학 조성물

Also Published As

Publication number Publication date
EP1280555B8 (fr) 2006-06-28
ES2264444T3 (es) 2007-01-01
CZ20023587A3 (cs) 2003-06-18
KR20020093971A (ko) 2002-12-16
MXPA02010865A (es) 2003-03-27
ATE326241T1 (de) 2006-06-15
JP2003535823A (ja) 2003-12-02
DE60119723D1 (de) 2006-06-22
WO2001082920A3 (fr) 2002-07-18
EP1280555A2 (fr) 2003-02-05
CA2407929C (fr) 2009-05-19
HUP0300632A3 (en) 2006-02-28
CA2407929A1 (fr) 2001-11-08
BR0110566A (pt) 2003-04-01
AU2001249364A1 (en) 2001-11-12
HUP0300632A2 (hu) 2003-08-28
PL358544A1 (en) 2004-08-09
ZA200209367B (en) 2004-02-18
NZ522641A (en) 2003-10-31
SK15532002A3 (sk) 2003-08-05
DE60119723T2 (de) 2007-04-26
CN1431915A (zh) 2003-07-23
EP1280555B1 (fr) 2006-05-17
WO2001082920A2 (fr) 2001-11-08

Similar Documents

Publication Publication Date Title
IN2012DN00606A (fr)
DE60336850D1 (en) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
EP1177168A4 (fr) Inhibiteurs de la caspase et leur utilisation
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
NO20074657L (no) Nitrogenholdige aromatiske ringforbindelser
FI964815A (fi) Piperatsiinijohdoksia 5-HT1A antagonisteina
AP2002002637A0 (en) Novel piperazine
NO20020938D0 (no) Substituerte alfa-hydroksysyre-caspaseinhibitorer og deres anvendelse
GB9919673D0 (en) 2-Arlybenzazole compounds
ATA16597A (de) Neue substituierte p-sulfonylaminobenzol- sulfonsäureamide
TR200000786T2 (tr) Vitronektin reseptör antagonisti
NO20025054D0 (no) Oksidasjonsprosess for fremstilling av mellomproduktet 6.alfa., 9.alfa.-difluor-11.beta., 17.alfa.-dihydroksy-16.alfa.-metyl-androst-1,4-dien-3-on 17.beta.-karboksylsyre
UA83012C2 (ru) Кристаллическая форма натриевой соли 3-пиридил-1-гидроксиэтилиден-1,1-бисфосфоновой кислоты
YU48103A (sh) Litijumovi kompleksi n-(1-hidroksimetil-2,3-dihidroksipropil) 1,4,7-triskarboksimetil 1,4,7,10-tetraazaciklododekana, njihovo dobijanje i primena
IL152590A0 (en) Treatment of congestive heart failure
ES8607218A1 (es) Un procedimiento para preparar compuestos de amidina
MXPA04004213A (es) Utilizacion de derivados de 2-amino-4-piridilmetil-tiazolina como inhibidores de no-sintasa inductible.
DE60216948D1 (en) 4'-methansulfonylbiphenylderivate als hochselektive cyclooxygenase-2-inhibitoren
HU0203193D0 (fr)
TR200200614T2 (tr) Vitronektin reseptörü antagonistleri
TR200300551T2 (tr) Agrokimyasal kompozisyon
ATE294790T1 (de) Chlormethylierung von thiophene
YU43499A (sh) Kristalna hidratovana natrijumova so (e)-4,6-dihloro-3- (2-okso-1-fenilpirolidin-3-iliden metil)-1h-indol-2- karboksilne kiseline
GB9914085D0 (en) New use
DE60227113D1 (de) Kondensierte camptothecine als antitumormittel